[go: up one dir, main page]

JP2004089004A5 - - Google Patents

Download PDF

Info

Publication number
JP2004089004A5
JP2004089004A5 JP2002250574A JP2002250574A JP2004089004A5 JP 2004089004 A5 JP2004089004 A5 JP 2004089004A5 JP 2002250574 A JP2002250574 A JP 2002250574A JP 2002250574 A JP2002250574 A JP 2002250574A JP 2004089004 A5 JP2004089004 A5 JP 2004089004A5
Authority
JP
Japan
Prior art keywords
disease
diseases
syndrome
muscle
cerebrospinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002250574A
Other languages
English (en)
Other versions
JP2004089004A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2002250574A priority Critical patent/JP2004089004A/ja
Priority claimed from JP2002250574A external-priority patent/JP2004089004A/ja
Publication of JP2004089004A publication Critical patent/JP2004089004A/ja
Publication of JP2004089004A5 publication Critical patent/JP2004089004A5/ja
Pending legal-status Critical Current

Links

Description

【0012】
本発明の補完療法のための栄養補助食品の成分であるRNA等は、上述のように、栄養補助食品として有用であり、脳脊髄性疾患の症状を改善するのに供されている(特公平6−69953公報(公告日 平成6年(1994)9月7日)を参照)。脳脊髄性疾患の例として、特に脳脊髄退行性疾患があり、その例としては、老人性ボケを含む痴呆症、てんかん症、痙攣発作、脳変性疾患、脳神経疾患、脳基底核疾患、小脳の変性疾患、脊髄変性疾患及び筋疾患等が挙げられる。
更に脳脊髄退行性疾患の具体的な例としてはてんかん症、痙攣発作及び脳変性疾患、例えば変性汎発性硬化症〔パレチユウスー(Pelizaeus)−メンツバツヒエル(Merzbacher)病、シヨルツ(Scholz)病、クラツベ(Krabbe)病〕、その他の先天性遺伝性疾患〔黒内障性家族性白痢、ローレンス(Lourence)−ムーン(Moon)−バーデツト(Bordet)−ビード(Bied):症候群、ガーゴイリズム〕、老年及び初老期脳疾患(老年痴呆、アルツハイマー病、ピツク病)、及び脳神経疾患例えば進行性球麻痺、進行性眼筋麻痺、遺伝性眼球振盪、アデイー(Adie)症候群、延髄空洞症、レーベル(Lebcr)病及び脳基底核疾患、例えばパーキンソン病、舞踏病疾候群、ジストニー症候群、アテトーゼ症候群、ミオクロニー症候群、振顫麻痺、小脳の変性疾患、例えば遺伝性脊髄性及び小脳性失調症、筋萎縮を伴なう遺伝性失調性、筋疾患、例えば進行性筋ジストロフイー症、重症筋無力症、週期性四肢麻痺、ミトコンドリア病(ミトコンドリア脳筋症)等が挙げられる。
JP2002250574A 2002-08-29 2002-08-29 アルギニンとrnaを含有する補完療法のための栄養補助食品 Pending JP2004089004A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2002250574A JP2004089004A (ja) 2002-08-29 2002-08-29 アルギニンとrnaを含有する補完療法のための栄養補助食品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2002250574A JP2004089004A (ja) 2002-08-29 2002-08-29 アルギニンとrnaを含有する補完療法のための栄養補助食品

Publications (2)

Publication Number Publication Date
JP2004089004A JP2004089004A (ja) 2004-03-25
JP2004089004A5 true JP2004089004A5 (ja) 2005-02-03

Family

ID=32057369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002250574A Pending JP2004089004A (ja) 2002-08-29 2002-08-29 アルギニンとrnaを含有する補完療法のための栄養補助食品

Country Status (1)

Country Link
JP (1) JP2004089004A (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4521488B2 (ja) 2008-08-21 2010-08-11 福美 森重 線維筋痛症候群の治療剤並びに筋攣縮による疼痛の治療剤
JP2010070463A (ja) * 2008-09-16 2010-04-02 Fukumi Morishige 栄養ドリンク剤
JP2013049671A (ja) * 2011-08-04 2013-03-14 Fancl Corp アスコルビン酸製剤

Similar Documents

Publication Publication Date Title
WO2003103583A8 (en) METHOD OF USING BIS (POLYHYDROXYPHENYLES) AND CORRESPONDING, FIXED O-ALKYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE CENTRAL NERVOUS SYSTEM
PT1511710E (pt) Compostos, composições e métodos para o tratamento de doenças da amiloide e sinucleínopatias tais como doença de alzheimer, diabetes do tipo 2, e doença de parkinson
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
WO2003041701A3 (en) Preparation for improving the action of receptors
JP2013526507A5 (ja)
AP2008A (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them
PL376769A1 (pl) Nowe związki tricykliczne użyteczne w leczeniu chorób zapalnych i alergicznych, sposób ich wytwarzania i kompozycje farmaceutyczne je zawierające
AU2003263393A1 (en) New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
CA2304965A1 (en) ((cyclo)alkyl substituted)-gamma-aminobutyric acid derivatives (=gaba analogues), their preparation and their use in the treatment of neurological disorders
EP2287165A3 (en) Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
WO2008060364A3 (en) Humani zed antibody against amyloid beta
WO2003027068A3 (en) Substituted amines for the treatment of neurological disorders
WO2008111590A3 (en) Ampa and nmda receptor antagonists for neurodegenerative diseases
JP2013528597A5 (ja)
TW200502221A (en) Novel lactams and uses thereof
TW200745135A (en) Therapeutic agents
WO2006119170A3 (en) Use of cytokine-derived peptides in treatment of pain and neurodegenerative disease
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
WO2007141346A3 (en) Genes regulating intracellular cholesterol trafficking as targets for treatment of cholesterol-related diseases
JP2004089004A5 (ja)
AU2002304329A1 (en) Methods for regulation of immune responses to conditions involving mediator-induced pathology
WO2004055201A3 (en) Cholesterol 24-hydroxylase (cyp46) as therapeutic target for the treatment of alzheimer's disease
WO2005003103A3 (en) 2, 4, 6-tri-substituted 6-membered heterocycles and their use in the treatment of neurodegenerative diseases
WO2012030050A3 (ko) 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
WO2006058720A3 (en) Novel compounds for the treatment of neurological disorders